뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 80mg - tablet - 10/80mg - active: ezetimibe 10mg simvastatin 80mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - podophyllotoxin 0.15%{relative} - topical cream - 0.15% w/w - active: podophyllotoxin 0.15%{relative} excipient: butylated hydroxyanisole cetyl alcohol emulsifying wax isopropyl myristate liquid paraffin medium-chain triglycerides methyl hydroxybenzoate phosphoric acid propyl hydroxybenzoate purified water sorbic acid stearyl alcohol - for the topical treatment of external condylomata acuminata (anogenital warts).

이스라엘 - 영어 - Ministry of Health

j-c health care ltd - miconazole nitrate - cream - miconazole nitrate 20 mg/g - miconazole - miconazole - broad spectrum antimycotic

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin, quantity: 0.5 mg/g - cream - excipient ingredients: propylene glycol; purified water; peg-40 stearate; white soft paraffin; propyl hydroxybenzoate; disodium edetate; stearyl alcohol; stearic acid; methyl hydroxybenzoate; butylated hydroxytoluene; isopropyl palmitate; butylated hydroxyanisole - indicated for use in the treatment of acne vulgaris, in particular forms where comedones, papules and pustules predominate.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin, quantity: 0.25 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propylene glycol; propyl hydroxybenzoate; white soft paraffin; purified water; stearic acid; peg-40 stearate; butylated hydroxyanisole; butylated hydroxytoluene; stearyl alcohol; isopropyl palmitate; disodium edetate - indicated for use in the treatment of acne vulgaris, in particular forms where comedones, papules and pustules predominate.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fusidic acid 20.35 mg/g (as the 0.5 hydrate) - topical cream - 20 mg/g - active: fusidic acid 20.35 mg/g (as the 0.5 hydrate) excipient: butylated hydroxyanisole cetyl alcohol glycerol hydrochloric acid liquid paraffin polysorbate 60 potassium sorbate purified water white soft paraffin - indicated either alone or in combination with systemic therapy, in the treatment of primary and secondary skin infections caused by sensitive strains of staphylococcus aureus, streptococcus spp and corynebacterium minutissimum. primary skin infections that may be expected to respond to treatment with fusidic acid applied topically include: impetigo contagiosa, superficial folliculitis, sycosis barbae, paronychia and erythrasma; also such secondary skin infections as infected eczematoid dermatitis, infected contact dermatitis and infected cuts/abrasions.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - netupitant, quantity: 300 mg; palonosetron hydrochloride, quantity: 0.56 mg (equivalent: palonosetron, qty 0.5 mg) - capsule - excipient ingredients: microcrystalline cellulose; sucrose laurate; povidone; croscarmellose sodium; purified water; silicon dioxide; sodium stearylfumarate; magnesium stearate; glyceryl caprylate/caprate; glycerol; polyglyceryl-3 dioleate; butylated hydroxyanisole; nitrogen; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; sorbitol; 1,4-sorbitan; mannitol - akynzeo is indicated in adult patients for: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; butylated hydroxyanisole; lactose monohydrate; citric acid monohydrate; ascorbic acid; titanium dioxide; hypromellose; hyprolose; purified talc; iron oxide yellow - adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

미국 - 영어 - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1